Provided by Tiger Fintech (Singapore) Pte. Ltd.

Myers

15.63
+0.58003.85%
Post-market: 15.630.00000.00%16:04 EDT
Volume:221.84K
Turnover:3.44M
Market Cap:584.29M
PE:55.79
High:15.63
Open:15.10
Low:15.05
Close:15.05
Loading ...

Myers Industries Q1 Sales USD 206.75 Million

THOMSON REUTERS
·
01 May

Myers Industries Announces First Quarter 2025 Results

Business Wire
·
01 May

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
01 May

Bristol-Myers' New Injection Version of Opdivo Gets UK Approval

MT Newswires Live
·
30 Apr

Press Release: DSMA FACILITATES SALE OF MCGRATH VOLVO CARS OF FORT MYERS TO KRAUSE AUTO GROUP

Dow Jones
·
29 Apr

Myers Industries Inc expected to post earnings of 19 cents a share - Earnings Preview

Reuters
·
29 Apr

Bristol Myers price target lowered to $53 from $62 at Wells Fargo

TIPRANKS
·
25 Apr

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

Dow Jones
·
25 Apr

Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results

Benzinga
·
25 Apr

Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

Benzinga
·
24 Apr

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

Dow Jones
·
24 Apr

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

Dow Jones
·
24 Apr

Bristol Myers: Q1 Earnings Snapshot

Associated Press Finance
·
24 Apr

Bristol Myers Squibb Reports First Quarter Financial Results for 2025

Business Wire
·
24 Apr

Investors in Myers Industries (NYSE:MYE) have unfortunately lost 53% over the last year

Simply Wall St.
·
24 Apr

Clever Culture Systems Receives Second Bristol Myers Squibb Facility Order for Technology, Shares Jump 6%

MT Newswires Live
·
24 Apr

Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

ACCESS Newswire
·
24 Apr

Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook -- Barrons.com

Dow Jones
·
23 Apr

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Zacks
·
23 Apr

Bristol Myers Stock Falls After Drug Trial Setback. Why 1 Analyst Isn't Worried. -- Barrons.com

Dow Jones
·
23 Apr